Document Type : Original Article


1 Assistant professor. Department of Biology, Yadegar-e-Imam Khomeini (RAH) Shahr-e-Rey Branch, Islamic Azad University, Tehran, Iran

2 Assistant professor. Department of Chemistry, Damghan Branch, Islamic Azad University, Damghan, Iran

3 Master student . Young Researchers and Elite Club, Yadegar-e-Imam Khomeini (RAH) Shahr-e-Rey Branch, Islamic Azad University, Tehran, Iran


Introduction and Aim: Drug nanocarriers have been used extensively in cancer therapy due to their features like the ability to targeting drug transmission, increasing drug solubility, and reducing the drug cytotoxic effects on healthy tissues. The purpose of this study was to investigate the effects of Tamoxifen nanocapsules on the expression of Bax and Bak genes in MCF-7 cell lines.
Methods: In this study, the nanocapsule structure was confirmed by FTIR spectroscopy and the effects of Tamoxifen nanocapsules on cell bioactivity were evaluated by MTT assay at concentrations of 10, 50, 100, and 200 µg/mL after 48 hours. Real-time PCR was used to analyze the expression of Bax and Bak genes and data were analyzed using SPSS (23.0) software.
Results: According to the MTT assay, higher concentrations of Tamoxifen nanocapsules decreased cell bioactivity in a dose-dependent manner and the highest toxicity of nanocapsules was at the concentration of 200 µg/mL. The expression level of Bax and Bak genes in MCF-7 treated cells after 48 hours indicated the induction of apoptosis in cells. The results revealed a 1.8-fold increase in cytotoxicity of Tamoxifen nanocapsules compared to free Tamoxifen.
Conclusion: The apoptosis induction as a result of increased expression of Bax and Bak genes and enhanced cytotoxicity, makes Tamoxifen nanocapsules a promising treatment for breast cancer therapy compared to free Tamoxifen.


Main Subjects

Abdel-Hafiz, H.A. 2017. Epigenetic mechanisms of tamoxifen resistance in luminal breast cancer. Diseases, 5(3): 16.
Behdarvand, N., Torbati, M.B. and Shaabanzadeh, M. 2020. Tamoxifen-loaded pla/dppe-peg lipid-polymeric nanocapsules for inhibiting the growth of estrogen-positive human breast cancer cells through cell cycle arrest. Journal of Nanoparticle Research, 22(9): 1-15.
De Oliveira, C.P., Büttenbender, S.L., Prado, W.A., Beckenkamp, A., Asbahr, A.C., Buffon, A., Guterres, S.S. and Pohlmann, A.R. 2018. Enhanced and selective antiproliferative activity of methotrexate-functionalized-nanocapsules to human breast cancer cells (mcf-7). Nanomaterials, 8(1): 24.
Dong, P., Rakesh, K., Manukumar, H., Mohammed, Y.H.E., Karthik, C., Sumathi, S., Mallu, P. and Qin, H.-L. 2019. Innovative nano-carriers in anticancer drug delivery-a comprehensive review. Bioorganic chemistry, 85: 325-336.
Gakhar, G., Hua, D.H. and Nguyen, T.A. 2010. Combinational treatment of gap junctional activator and tamoxifen in breast cancer cells. Anti-cancer drugs, 21(1): 77.
Guven, A., Rusakova, I.A., Lewis, M.T. and Wilson, L.J. 2012. Cisplatin@ us-tube carbon nanocapsules for enhanced chemotherapeutic delivery. Biomaterials, 33(5): 1455-1461.
Han, N.-n., Zhou, Q., Huang, Q. and Liu, K.-j. 2017. Carnosic acid cooperates with tamoxifen to induce apoptosis associated with caspase-3 activation in breast cancer cells in vitro and in vivo. Biomedicine & Pharmacotherapy, 89: 827-837.
Hekmat, A., Afrough, M., Hesami Tackallou, S. and Ahmad, F. 2020. Synergistic effects of titanium dioxide nanoparticles and paclitaxel combination on the DNA structure and their antiproliferative role on mda-mb-231cells. Journal of Nanoanalysis: -. DOI 10.22034/jna.2020.1869287.1141.
Hekmat, A. and Roshani, Z. 2020. The effects of silver nanoparticles coatings in effective drug delivery: Human serum albumin interaction. Journal of Fasa University of Medical Sciences, 10(2): 2294-2307.
Hultsch, S., Kankainen, M., Paavolainen, L., Kovanen, R.-M., Ikonen, E., Kangaspeska, S., Pietiäinen, V. and Kallioniemi, O. 2018. Association of tamoxifen resistance and lipid reprogramming in breast cancer. BMC cancer, 18(1): 1-14.
Kathle, P.K., Gautam, N. and Kesavan, K. 2018. Tamoxifen citrate loaded chitosan-gellan nanocapsules for breast cancer therapy: Development, characterisation and in-vitro cell viability study. Journal of microencapsulation, 35(3): 292-300.
Kim, R. 2005. Unknotting the roles of bcl-2 and bcl-xl in cell death. Biochemical and biophysical research communications, 333(2): 336-343.
Kumari, P., Ghosh, B. and Biswas, S. 2016. Nanocarriers for cancer-targeted drug delivery. Journal of drug targeting, 24(3): 179-191.
Lila, A.S.A., Kiwada, H. and Ishida, T. 2014. Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatin. Biological and Pharmaceutical Bulletin, 37(2): 206-211.
Lindsten, T., Ross, A.J., King, A., Zong, W.-X., Rathmell, J.C., Shiels, H.A., Ulrich, E., Waymire, K.G., Mahar, P. and Frauwirth, K. 2000. The combined functions of proapoptotic bcl-2 family members bak and bax are essential for normal development of multiple tissues. Molecular cell, 6(6): 1389-1399.
Nankali, E., Shaabanzadeh, M. and Torbati, M.B. 2020. Fluorescent tamoxifen-encapsulated nanocapsules functionalized with folic acid for enhanced drug delivery toward breast cancer cell line mcf-7 and cancer cell imaging. Naunyn-Schmiedeberg's archives of pharmacology, 393(7): 1211-1219.
Olsen, S.N., Wronski, A., Castaño, Z., Dake, B., Malone, C., De Raedt, T., Enos, M., DeRose, Y.S., Zhou, W. and Guerra, S. 2017. Loss of rasgap tumor suppressors underlies the aggressive nature of luminal b breast cancers. Cancer discovery, 7(2): 202-217.
Papaliagkas, V., Anogianaki, A., Anogianakis, G. and Ilonidis, G. 2007. The proteins and the mechanisms of apoptosis: A mini-review of the fundamentals. Hippokratia, 11(3): 108.
Saxena, M., Kryworuchko, M. and Kumar, A. 2009. Anti-apoptotic genes in the survival of monocytic cells during infection. Current genomics, 10(5): 306-317.
Singh, S.K., Banala, V.T., Gupta, G.K., Verma, A., Shukla, R., Pawar, V.K., Tripathi, P. and Mishra, P.R. 2015. Development of docetaxel nanocapsules for improving in vitro cytotoxicity and cellular uptake in mcf-7 cells. Drug development and industrial pharmacy, 41(11): 1759-1768.
Thomas, S., Thurn, K.T., Biçaku, E., Marchion, D.C. and Münster, P.N. 2011. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast cancer research and treatment, 130(2): 437-447.
Wang, Q., Jiang, J., Ying, G., Xie, X.-Q., Zhang, X., Xu, W., Zhang, X., Song, E., Bu, H. and Ping, Y.-F. 2018. Tamoxifen enhances stemness and promotes metastasis of erα36+ breast cancer by upregulating aldh1a1 in cancer cells. Cell research, 28(3): 336-358.